 |
|
|
 |
Grant Program Overview
The Genzyme Renal Innovations Grant Program (GRIP) distributes individual grants to researchers, clinicians and fellows in the field of Nephrology. GRIP was established to support the advancement of medical knowledge and practice in kidney diseases through innovative research projects in Nephrology. It represents the commitment Genzyme has made to enhance the care of patients with kidney disease. As we pursue new knowledge and understanding together, our hope is to sustain an enduring partnership with the worldwide Nephrology community.
Grant topics for 2009 will be announced at the American Society of Nephrology (ASN) annual meeting in November 2008. All applicants must submit a Letter of Intent which is due in January 2009. If the proposed research is selected, the applicant will be notified via email and asked to submit a full research proposal. Full research proposals are due before March 31, 2009 and winners will be announced at the annual European Dialysis and Transplant Association (EDTA) meeting held in mid 2009. An independent medical review board composed of worldwide thought leaders in the Nephrology community will review and evaluate all Letters of Intent and proposals.
Contact Information
For questions regarding the GRIP program or grant application process, please email grip@genzyme.com. You may also call within the US 1-800-326-7002, x16658, or +1-617-768-6658 outside the US, and speak with Susan Kapurch, Grant Program Administrator.
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel. Patients should be informed to take Renagel with meals and to adhere to their prescribed diets. See Renagel Full Prescribing Information. For more information, please see Full Prescribing Information for Renagel or call Genzyme Medical Information at 1-800-847-0069. | |
|
|
|
Genzyme Corporate
